Immunic, Inc. (IMUX) Stock Score, Valuation & Financial Research

Immunic, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IMUX

Immunic, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 9.30. These figures are a research snapshot, not a buy or sell recommendation.

What Immunic, Inc. does

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Immunic, Inc. is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and debt financing to fund the research and development of its pipeline of oral immunology therapies for chronic inflammatory and autoimmune diseases.

Products and services

  • The company is developing a pipeline of selective oral immunology therapies, including vidofludimus calcium (IMU-838) for multiple sclerosis and other autoimmune diseases, and IMU-856 for gastrointestinal diseases.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various third-party contract research organizations to conduct its clinical trials and manage data collection. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes third-party contract manufacturing organizations for the production of its clinical trial drug supplies. Source

Business strengths to evaluate

  • Clinical pipeline of selective oral immunology therapies Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of clinical trials and regulatory approval Source
  • Need for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IMUX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 9.30
Market capitalization:
126.68M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -111.57M
Free cash flow:
USD -85.97M
Cash:
USD 155.1M
Total debt:
USD 567K
EPS:
USD -4.80

What stands out

  • Free cash flow is USD -85.97M, negative for the stored period.
  • The balance sheet shows USD 155.1M of cash versus USD 567K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 154.53M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IMUX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can IMUX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IMUX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IMUX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IMUX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research IMUX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.